These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37699634)

  • 1. Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial).
    Pang K; Yang Y; Tian D; Zeng N; Cao S; Ling S; Gao J; Zhao P; Wang H; Kong Y; Zhang J; Chen G; Deng W; Bai Z; Jin L; Wu G; Zhu D; Wang Y; Zhou J; Wu B; Lin G; Xiao Y; Gao Z; Ye Y; Wang X; Li A; Han J; Yao H; Yang Y; Zhang Z
    BMJ Open; 2023 Sep; 13(9):e069499. PubMed ID: 37699634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study protocol of short-course radiotherapy combined with CAPOX and PD-1 inhibitor for locally advanced colon cancer: a randomised, prospective, multicentre, phase II trial (TORCH-C).
    Zhang H; Li Y; Xia F; Sun Y; Shen L; Wan J; Chen Y; Wang Y; Zhou M; Wu R; Zhou S; Wang Y; Liu F; Cai S; Zhang Z
    BMJ Open; 2024 Feb; 14(2):e079442. PubMed ID: 38309748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E).
    Chen Y; Wang Y; Zhang H; Wan J; Shen L; Wang Y; Zhou M; Wu R; Yang W; Zhou S; Cai S; Li X; Zhang Z; Xia F
    BMJ Open; 2023 Oct; 13(10):e076048. PubMed ID: 37802608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).
    Yang Z; Zhang X; Zhang J; Gao J; Bai Z; Deng W; Chen G; An Y; Liu Y; Wei Q; Han J; Li A; Liu G; Sun Y; Kong D; Yao H; Zhang Z
    BMC Cancer; 2022 Apr; 22(1):462. PubMed ID: 35477432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer (NECI Study): a protocol for a phase II study.
    Fan Y; Zhu X; Xu C; Ding C; Hu J; Hong Q; Wang J
    BMJ Open; 2023 Mar; 13(3):e069401. PubMed ID: 36914193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Node-sparing modified short-course Radiotherapy Combined with CAPOX and Tislelizumab for locally Advanced MSS of Middle and low rectal Cancer (mRCAT): an open-label, single-arm, prospective, multicentre clinical trial.
    Cai C; Zhang X; Sun X; Wang H; Chen E; Chen L; Gu B; Wang J; Huang X; Lao W; Wang X; Chen M; Ding S; Du J; Song Z
    BMC Cancer; 2024 Oct; 24(1):1247. PubMed ID: 39385104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)].
    Wang YQ; Shen LJ; Wan JF; Zhang H; Wang Y; Wu X; Wang JW; Wang RJ; Sun YQ; Tong T; Huang D; Wang L; Sheng WQ; Zhang X; Cai GX; Xu Y; Cai SJ; Zhang Z; Xia F
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):448-458. PubMed ID: 37217353
    [No Abstract]   [Full Text] [Related]  

  • 8. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT).
    Hanna CR; O'Cathail SM; Graham JS; Saunders M; Samuel L; Harrison M; Devlin L; Edwards J; Gaya DR; Kelly CA; Lewsley LA; Maka N; Morrison P; Dinnett L; Dillon S; Gourlay J; Platt JJ; Thomson F; Adams RA; Roxburgh CSD
    Radiat Oncol; 2021 Aug; 16(1):163. PubMed ID: 34446053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial.
    Chen J; Han Y; Hu Y; Feng X; Meng X; Guo S; Sun C; Chen G; Li K
    BMJ Open; 2023 May; 13(5):e067767. PubMed ID: 37253491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial.
    Huang CY; Bai MH; Shen JW; Sun QQ; Feng YR; Chen QP; Mao W; Ju HX; Zhu J
    BMC Cancer; 2024 Jan; 24(1):57. PubMed ID: 38200410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review.
    Yang L; Cui X; Wu F; Chi Z; Xiao L; Wang X; Liang Z; Li X; Yu Q; Lin X; Gao C
    Front Immunol; 2024; 15():1392499. PubMed ID: 38846948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).
    Akiyoshi T; Shinozaki E; Taguchi S; Chino A; Hiratsuka M; Tominaga T; Nonaka T; Toda S; Matoba S; Matsui S; Okabayashi K; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Yamaguchi K; Ueno M; Kuroyanagi H; Fukunaga Y; Ishizuka N; Konishi T;
    BMJ Open; 2022 Mar; 12(3):e055140. PubMed ID: 35304396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer.
    Gao J; Zhang X; Yang Z; Zhang J; Bai Z; Deng W; Chen G; Xu R; Wei Q; Liu Y; Han J; Li A; Liu G; Sun Y; Kong D; Yao H; Zhang Z
    Front Oncol; 2023; 13():1057947. PubMed ID: 36816939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
    van den Berg K; Schaap DP; Voogt ELK; Buffart TE; Verheul HMW; de Groot JWB; Verhoef C; Melenhorst J; Roodhart JML; de Wilt JHW; van Westreenen HL; Aalbers AGJ; van 't Veer M; Marijnen CAM; Vincent J; Simkens LHJ; Peters NAJB; Berbée M; Werter IM; Snaebjornsson P; Peulen HMU; van Lijnschoten IG; Roef MJ; Nieuwenhuijzen GAP; Bloemen JG; Willems JMWE; Creemers GJM; Nederend J; Rutten HJT; Burger JWA
    BMC Cancer; 2022 Sep; 22(1):957. PubMed ID: 36068495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimisation of Organ Preservation treatment strategies in patients with rectal cancer with a good clinical response after neoadjuvant (chemo)radiotherapy: Additional contact X-ray brachytherapy versus eXtending the observation period and local excision (OPAXX) - protocol for two multicentre, parallel, single-arm, phase II studies.
    Geubels BM; van Triest B; Peters FP; Maas M; Beets GL; Marijnen CAM; Custers PA; Rutten HJT; Theuws JCM; Verrijssen AE; Cnossen JS; Burger JWA; Grotenhuis BA
    BMJ Open; 2023 Dec; 13(12):e076866. PubMed ID: 38159950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial.
    Yamazaki T; Gunderson AJ; Gilchrist M; Whiteford M; Kiely MX; Hayman A; O'Brien D; Ahmad R; Manchio JV; Fox N; McCarty K; Phillips M; Brosnan E; Vaccaro G; Li R; Simon M; Bernstein E; McCormick M; Yamasaki L; Wu Y; Drokin A; Carnahan T; To Y; Redmond WL; Lee B; Louie J; Hansen E; Solhjem MC; Cramer J; Urba WJ; Gough MJ; Crittenden MR; Young KH
    Lancet Oncol; 2022 Sep; 23(9):1189-1200. PubMed ID: 35952709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining chemotherapy and tislelizumab with preoperative split-course hypofraction radiotherapy for locally advanced rectal cancer: study protocol of a prospective, single-arm, phase II trial.
    Zheng R; Wang BS; Li Z; Chi P; Xu B
    BMJ Open; 2023 Mar; 13(3):e066976. PubMed ID: 36927585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
    Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
    Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rectal cancer (APHRODITE): protocol for a multicentre, open-label randomised controlled trial.
    Hudson EM; Noutch S; Brown S; Adapala R; Bach SP; Burnett C; Burrage A; Gilbert A; Hawkins M; Howard D; Jefford M; Kochhar R; Saunders M; Seligmann J; Smith A; Teo M; Webb EJ; Webster A; West N; Sebag-Montefiore D; Gollins S; Appelt AL
    BMJ Open; 2022 Apr; 12(4):e049119. PubMed ID: 35487526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.